期刊文献+

侵袭性白念珠菌小鼠感染模型的建立与评估 被引量:1

Establishment and evaluation of invasive Candida albicans infection model in mice
下载PDF
导出
摘要 目的建立侵袭性白念珠菌小鼠感染模型。方法体外通过菌丝生长实验评价白念珠菌的毒力大小,通过尾静脉注射白念珠菌菌悬液感染小鼠后,观察小鼠生存时间,评价白念珠菌体内毒力大小;以感染后7 d内小鼠100%死亡为标准,建立了侵袭性白念珠菌小鼠感染模型,对感染小鼠进行氟康唑治疗效果评价。结果白念珠菌体外毒力与体内毒力一致,4种培养基中菌丝均生长良好的菌株,体内感染小鼠后,小鼠生存率也最低;感染模型中,氟康唑对敏感白念珠菌的治疗效果强于对氟康唑耐药白念珠菌(P<0.05)。结论建立的侵袭性白念珠菌感染模型可用于药物体内抗白念珠菌活性的筛选。 Objective To establish an invasive Candida albicans infection model in mice. Methods The virulence of Candida albicans in vitro was evaluated by means of mycelial growth experiment,while that in vivo was evaluated through the mouse infection model;an aliquot of culture containing Candida albicans with 5 &#215; 105 CFU was injected into each mouse through the tail vein and the survival time of the infected mice was observed. 100% death of the mice within 7 days of infection was used as the successful establishment of the infection model;fluconazole was applied to the infected mice and the effect on the infection of Candida albicans was evaluated as well. Results Candida albicans had the same virulence in vitro and in vivo;strains were well inducted in the 4 hyphal induction media;the survival rate of the infected mice was very low;fluconazole was more effective on Candida albicans sensitive to it than on those resistant to it( P ﹤ 0. 05). Conclusions Invasive Candida albicans infection model in mice is applicable for drug screening of anti-Candida albicans activity in vivo.
出处 《西南国防医药》 CAS 2014年第7期697-700,共4页 Medical Journal of National Defending Forces in Southwest China
基金 国家自然科学基金资助项目(81173643 81330083)
关键词 白念珠菌 毒力 感染 小鼠 氟康唑 体内实验 Candida albicans virulence infection mice fluconazole in vivo
  • 相关文献

参考文献10

  • 1Cow NA, van de Veerdonk FL, Brown A J, et al. Candida albicans morphogenesis and host defence: discriminating invasion from colonization[ J ]. Nat Rev Microbio1,2012,10 : 112-122.
  • 2Eggimann P, Garbino J, Pittet D. Epidemiology of Candida species infections in critically ill non-immunosuppressed patients [ J ]. lancet Infect Dis ,2003,3:685-702.
  • 3Grim SA, Berger K, Teng C, et al. Timing of susceptibility-based antifungal drug administration in patients with Candida bloodstream infection : correlation with outcomes [ J ]. J Antimicrob Chemother, 2012,67 : 707 -714.
  • 4Slavin MA, Sorrell TC, Marriott D, et al. Candidaemia in adult cancer patients : risks for flueonazole-resistant isolates and death[ J ]. J Antimicreb Chemother,2010,65 : 1042-1051.
  • 5Chopra I. The 2012 Garrod lecture : discovery of antibacterial drugs in the 21st century[ J]. J Antimicrob Chemother,2013,68:496- 505.
  • 6Wise R. The urgent need for new antibacterial agents [ J ]. J Anti- microb Chemother,2011,66:1939-1340.
  • 7Livermore DM. Discovery research:the scientific challenge of finding new antibiotics [ J ]. J Antimierob Chemother,2011,66:1941-1944.
  • 8Lee KL,Buckley HR,Campbell CC. An amino acid liquid synthetic medium for the development of myeelial and yeast forms of Cand/daAlbicans [ J ]. Sabouraudia, 1975,13 : 148-153.
  • 9Klotz SA, Drutz DJ, Zajie JE. Factors governing adherence of Candida species to plastic surfaces[ J]. Infect Immun, 1985,50: 97-101.
  • 10Mayer FL, Wilson D, Hube B. Candida albicans pathogenicity mechanisms[ J]. Virulence,2013,4 : 119-128.

同被引文献4

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部